Scarica l'app Stockscreener
71.11
2.13%
-1.55
Dopo l'orario di chiusura:
71.73
0.62
+0.87%
Precedente Chiudi:
$72.66
Aprire:
$72.25
Volume 24 ore:
453.88K
Relative Volume:
0.58
Capitalizzazione di mercato:
$2.06B
Reddito:
$915.25M
Utile/perdita netta:
$131.14M
Rapporto P/E:
15.90
EPS:
4.472
Flusso di cassa netto:
$96.71M
1 W Prestazione:
+3.37%
1M Prestazione:
+2.97%
6M Prestazione:
+26.19%
1 anno Prestazione:
-11.30%
Intervallo 1D:
$68.44
$72.75
Intervallo di 1 settimana:
$68.44
$73.29
Portata 52W:
$38.91
$147.03
Inspire Medical Systems Inc Stock (INSP) Company Profile
Nome
Inspire Medical Systems Inc
Settore
Industria
Telefono
763-957-5037
Indirizzo
5500 WAYZATA BLVD, GOLDEN VALLEY
Compare INSP vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSP
Inspire Medical Systems Inc
|
71.11 | 2.06B | 915.25M | 131.14M | 96.71M | 4.472 |
ABT
Abbott Laboratories
|
103.70 | 179.44B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.41 | 122.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.19 | 117.83B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.67 | 66.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.04 | 51.32B | 6.30B | 1.07B | 1.09B | 1.8406 |
Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-07 | Iniziato | Barclays | Underweight |
| 2026-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-07-28 | Ripresa | UBS | Sell |
| 2026-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2026-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2026-05-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2026-02-13 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-02-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2026-01-22 | Downgrade | Truist | Buy → Hold |
| 2025-12-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-26 | Aggiornamento | Truist | Hold → Buy |
| 2025-11-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-11-24 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-24 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-22 | Downgrade | UBS | Buy → Neutral |
| 2025-09-02 | Iniziato | Evercore ISI | Outperform |
| 2025-08-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-08-05 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-08-05 | Downgrade | Truist | Buy → Hold |
| 2024-11-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-04-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2024-01-19 | Iniziato | Jefferies | Buy |
| 2024-01-02 | Downgrade | Stifel | Buy → Hold |
| 2023-12-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-12-13 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Peer Perform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-12-15 | Downgrade | Goldman | Buy → Neutral |
| 2020-11-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-11-03 | Aggiornamento | Oppenheimer | Underperform → Perform |
| 2020-09-22 | Iniziato | JP Morgan | Overweight |
| 2020-09-02 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-07-15 | Iniziato | Goldman | Buy |
| 2020-06-18 | Reiterato | Piper Sandler | Overweight |
| 2020-05-18 | Iniziato | Lake Street | Buy |
| 2020-04-28 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-04-09 | Iniziato | Piper Sandler | Overweight |
| 2020-01-28 | Iniziato | Oppenheimer | Underperform |
| 2020-01-27 | Iniziato | Oppenheimer | Underperform |
| 2019-11-06 | Aggiornamento | Berenberg | Sell → Hold |
| 2019-02-05 | Iniziato | Dougherty & Company | Buy |
| 2018-11-28 | Iniziato | Berenberg | Sell |
| 2018-10-29 | Iniziato | Leerink Partners | Outperform |
| 2018-05-29 | Iniziato | Guggenheim | Buy |
| 2018-05-29 | Iniziato | Stifel | Buy |
| 2018-05-29 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Inspire Medical Systems Inc Borsa (INSP) Ultime notizie
Here's How Tempus AI Demonstrates Improving Operating Leverage - Zacks Investment Research
A director receives 203 shares instead of cash fees at Inspire Medical Systems (INSP). - Stock Titan
A director receives 284 shares instead of cash fees at Inspire Medical Systems (INSP) - Stock Titan
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo! Finance Canada
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo Finance
Truist Securities Adjusts Inspire Medical Systems PT to $78 From $62, Maintains Hold Rating - Yahoo Finance
Inspire Medical Systems Inc. (US4577301090.SG) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Mizuho Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Inspire Medical Systems Inc (INSP) Shares Surge 3.8% -- What GF Score of 64 Tells Investors - GuruFocus
Free cash flow per share of Inspire Medical Systems, Inc. – HAM:2DR - TradingView
Price to cash flow ratio of Inspire Medical Systems, Inc. – HAN:2DR - TradingView
Inspire Medical Systems Inc. (US4577301090.SG) Q1 FY2026 earnings call transcript - Yahoo Finance
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo! Finance Canada
Inspire Medical Systems Inc (INSP) Stock Up 3.3% and Still Undervalued -- GF Score: 64/100 - GuruFocus
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Inspire Medical Systems, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Inspire Medical Systems Price Target Announced at $65.00/Share by Barclays - Moomoo
Barclays Initiates Inspire Medical Systems at Underweight With $65 Price Target - marketscreener.com
Barclays Initiates Inspire Medical Systems at Underweight With $65 Price Target - Yahoo Finance
Inspire Medical Systems Inc (INSP) Shares Fall 3.6% -- What GF S - GuruFocus
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo Finance UK
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo! Finance Canada
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 - Yahoo Finance
How Investors Are Reacting To Inspire Medical Systems (INSP) Securing Category I CPT Codes For Inspire V - Yahoo Finance
Medical Devices & SuppliesSpecialty Stocks Q2 Earnings Review: Inspire Medical Systems (NYSE:INSP) Shines - Yahoo Finance
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - Zacks Investment Research
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - TradingView
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation - Yahoo Finance
Inspire Medical (INSP): How Much Optimism Is Baked Into This Medtech Stock? - Yahoo Finance
RBC Capital Initiates Inspire Medical Systems(INSP.US) With Hold Rating, Announces Target Price $75 - Moomoo
Inspire Medical Systems, Inc. (INSP) stock price, news, quote and history - Yahoo Finance UK
INSP Maintains Buy Rating by Freedom Capital Markets -- Price Ta - gurufocus.com
Freedom Capital Markets maintains Buy rating on Inspire Medical Systems, $97 price target - TradingView
Top Inspire Medical Systems (INSP) Competitors 2026 - marketbeat.com
Inspire Medical receives new CPT codes for sleep apnea device - Investing.com
Inspire Medical Systems (INSP) Gains CPT Code Approval for Inspi - gurufocus.com
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel - The Manila Times
More than 140,000 patients have been treated for sleep apnea with Inspire. New billing codes are scheduled for 2028. - Stock Titan
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel - Yahoo Finance
Inspire Medical Systems Is Maintained at Sector Perform by RBC Capital - Moomoo
RBC Raises Price Target on Inspire Medical Systems to $75 From $60, Keeps Sector Perform Rating - marketscreener.com
INSP Maintained by RBC Capital -- Price Target Raised to $75 - gurufocus.com
Inspire Medical Systems Gets New CPT Codes for Hypoglossal Nerve Stimulation - Yahoo Finance
Inspire Medical Systems (NYSE:INSP) Stock Forecast & Analyst Predictions - Simply Wall Street
Inspire Medical Systems, Inc. (INSP) Stock Forecasts - Yahoo Finance
Inspire Medical Systems Inc (INSP) Stock Down 5.2% -- Now Underv - gurufocus.com
Inspire Medical Systems (INSP) Stock Could Be A Bargain On Cash Flow - Yahoo Finance
Inspire Medical Systems Inc (INSP) Stock Up 4.5% and Still Under - gurufocus.com
2DR Forecast — Price Target — Prediction for 2027 - TradingView
Inspire Medical Systems Inc Azioni (INSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inspire Medical Systems Inc Azioni (INSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| JASON P KELLY | Officer |
Aug 07 '26 |
Proposed Sale |
59.55 |
963 |
57,342 |
0 |
| Kelly Jason P | See Remarks |
Aug 07 '26 |
Sale |
59.55 |
963 |
57,347 |
18,985 |
| Rondoni John | See Remarks |
May 15 '26 |
Sale |
43.28 |
2,641 |
114,302 |
27,165 |
| JOHN RONDONI | Officer |
May 15 '26 |
Proposed Sale |
43.28 |
2,641 |
114,304 |
0 |
| Rondoni John | See Remarks |
May 14 '26 |
Sale |
43.01 |
700 |
30,107 |
29,806 |
| JOHN RONDONI | Officer |
May 14 '26 |
Proposed Sale |
43.01 |
700 |
30,106 |
0 |
| mcCormick Shawn | Director |
May 08 '26 |
Sale |
45.31 |
696 |
31,536 |
27,712 |
| SHAWN T MCCORMICK | Director |
May 08 '26 |
Proposed Sale |
45.57 |
696 |
31,717 |
0 |
| JOHN RONDONI | Officer |
Jan 09 '26 |
Proposed Sale |
95.00 |
109 |
10,355 |
0 |
| Rondoni John | See Remarks |
Jan 09 '26 |
Sale |
100.00 |
109 |
10,900 |
13,797 |
3.13%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):